Presentient has developed a solution that allows for the early stopping of successful or failing trials, which accelerates the process of getting drugs to patients, saves billions for pharmaceutical companies, and reshapes industry risk. The technology is unique in that it maintains the integrity of blinded trial data while achieving a 99.7% prediction accuracy, validated on 15,000 simulated trials in partnership with a top 5 pharmaceutical company.